Choose the safety of EMERPHED® ready‑to‑use ephedrine.
Commercially prepared. FDA approved.

Choose the safety of EMERPHED® ready‑to‑use ephedrine.
Commercially prepared. FDA approved.

Choose the safety of EMERPHED® ready‑to‑use ephedrine.
Commercially prepared. FDA approved.

The first FDA approved, ready‑to‑use ephedrine.

Want one less thing to worry about in the OR? Choose the simplicity, stability, and safety of EMERPHED® ready-to-use ephedrine from Nexus Pharmaceuticals.

Ready to use. Less waste.

And no mixing means no mix-ups.

Prescribing Information

Redefining standards of care—the benefits of NEW EMERPHED


No compounding

EMERPHED® can be administered by any trained staff with less chance for error.


2-year shelf-life

EMERPHED® is ready when you need it with less frequent re-stocking/ordering.


No diluting or mixing

EMERPHED® is easier to use with less waste and chance for error.

Share and compare.
Take our short survey.

What does ready-to-use mean for your OR protocol? Compare your process with that of your colleagues.

No mixing.
No mix-ups.

See why the FDA recommends the use of non-compounded, manufacturer-prepared products.
What important safety information should I know?




EMERPHED can cause pressor effects with concomitant use with oxytocic drugs. Can also cause tachyphylaxis with repeated administration of ephedrine.


Most common adverse reactions during treatment: nausea, vomiting, and tachycardia.

To report SUSPECTED ADVERSE REACTIONS, contact Nexus Pharmaceuticals at (855) 642-2594 or FDA at 1-800-FDA-1088 or


  • Interactions that Augment Pressor Effect: clonidine, oxytocin and oxytocic drugs, propofol, monoamine oxidase inhibitors (MAOIs), and atropine. Monitor blood pressure.

  • Interactions that Antagonize the Pressor Effect: Antagonistic effects with α-adrenergic antagonists, β-adrenergic antagonists, reserpine, quinidine, mephentermine. Monitor blood pressure.

  • Guanethidine: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. Monitor blood pressure and adjust the dosage of pressor accordingly.

  • Rocuronium: Ephedrine may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction. Be aware of this potential interaction. No treatment or other interventions are needed.

  • Epidural anesthesia: Ephedrine may decrease the efficacy of epidural blockade by hastening the regression of sensory analgesia. Monitor and treat the patient according to clinical practice.

  • Theophylline: Concomitant use of ephedrine may increase the frequency of nausea, nervousness, and insomnia. Monitor patient for worsening symptoms and manage symptoms according to clinical practice.

  • Cardiac glycosides: Giving ephedrine with a cardiac glycoside, such as digitalis, may increase the possibility of arrhythmias. Carefully monitor patients on cardiac glycosides who are also administered ephedrine.


Overdose of EMERPHED can cause a rapid rise in blood pressure. In the case of an overdose, careful monitoring of blood pressure is recommended. If blood pressure continues to rise to an unacceptable level, parenteral antihypertensive agents can be administered at the discretion of the clinician.


Ephedrine Sulfate injection is an alpha- and beta- adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.